Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose esketamine for postoperative cognitive dysfunction after hip arthroplasty in elderly patients
ChiCTR2300067315Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of Hebei University
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in post-operative cognitive decline (POCD) (2 arms), sponsored by Affiliated Hospital of Hebei University. Primary endpoints: Mini-Mental State Examination score and Inflammatory factors. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
post-operative cognitive decline (POCD)
Beyond the preview
Go deeper on ChiCTR2300067315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067315.